Loading
Smoking Cessation / PRIDE QUIT / Anxiety · Interventional Study
ClinicalTrials.gov · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a terminated pilot feasibility and acceptability study of an adapted smoking cessation intervention (PRIDE QUIT) for transgender and gender expansive individuals. The study enrolled only 3 participants before termination, so no efficacy data or meaningful pilot results are available from this registry record. The primary outcomes—acceptability and feasibility—are planned measures but results are not reported here.
Interventional, Randomized, Parallel, Open label, Treatment purpose. Smoking Cessation, Depression, Anxiety, Nicotine Dependence, Gender Minority Stress; age from 18 Years. Intervention: PRIDE QUIT. Compared with: Enhanced Treatment As Usual (ETAU) — Active Comparator. n = 3. 3 sites: United States.
Study recruitment terminated early with only 3 participants enrolled (planned enrollment not stated). Primary outcomes were acceptability through approximately 10 weeks and feasibility through approximately 6 months of enrollment. Study addressed smoking cessation disparities in transgender and gender diverse individuals, incorporating gender minority stress and comorbid anxiety and depression into intervention design.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This terminated pilot cannot be used to guide clinical practice at this stage. Clinicians and researchers should note that a rigorous trial in this underserved population was initiated but not completed; results from completed studies are needed to inform smoking cessation approaches for transgender and gender diverse individuals.
This is a terminated pilot study with only 3 enrolled participants, designed to assess feasibility and acceptability of an adapted smoking cessation intervention; no efficacy results are reported in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
This terminated pilot cannot be used to guide clinical practice at this stage. Clinicians and researchers should note that a rigorous trial in this underserved population was initiated but not completed; results from completed studies are needed to inform smoking cessation approaches for transgender and gender diverse individuals.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Registry record from ClinicalTrials.gov (NCT06654414). This is a study registration, not published results. Lead sponsor: Massachusetts General Hospital. Recruitment status: TERMINATED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 3 participants (ACTUAL). Conditions: Smoking Cessation, Depression, Anxiety, Nicotine Dependence, Gender Minority Stress. Interventions: BEHAVIORAL: PRIDE QUIT; BEHAVIORAL: Enhanced Treatment As Usual (ETAU). Primary outcome measures: Acceptability , Through the end of treatment intervention, approximately 10 weeks; Feasibility of the Intervention , Through participants' enrollment, approximately 6 months. Brief summary: Smoking remains the leading preventable cause of death in the United States, and there are persistent and significant disparities in tobacco use among transgender and gender diverse (TGD) individuals. Stigma, discrimination, gender dysphoria, and other gender minority stressors likely contribute to these disparities, and the increased burden of gender minority stress may also be driving higher prevalence rates of anxiety and depression, both of which are more common among TGD individuals and among those who smoke relative to comparison samples. This study will (1) explore the ways in which gender minority stressors and associated anxiety and depression compromise smoking cessation among TGD individuals, identifying elements in an existing smoking cessation intervention that need to be adjusted to meet their unique needs; (2) adapt an existing smoking cessation intervention for TGD individuals; and (3) evaluate the feasibility and acceptability of the adapted intervention in a pilot randomized controlled trial.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.